The growth trend continues in the first 9 months of 2018: sales abroad exceed sales in italy

PharmaNutra SPA is pleased to report the significant sales results obtained once again in the first 9 months of 2018. Specifically, as already noted during the first half of the year, the company continues to grow at international level, where PharmaNutra continues to record impressive sales volumes. Forecasts for volumes indicate that by the end of the year, the company will have sold over six million units; approximately 58% of these sales are expected to be recorded on foreign markets (sales by volume).

The international figures represent an essential driver for growth, confirming the popularity of the Group’s products also outside of Italy.

Roberto Lacorte, Vice President of PharmaNutra, explains: “The figures registered by the Group are a source of strong motivation in all directions, but we are especially proud of the results achieved on foreign markets. One of the aims we set ourselves after listing was to boost our international presence, and we are succeeding in this. These figures, as well as reassuring us and confirming the interest in our products, also provide objective proof of the efficacy of our patented Sucrosomial® Technology, and represent an essential driver of growth for the Group”.

At international level, PharmaNutra has recently signed a partnership agreement with the Swiss company Fresenius Kabi Switzerland for the distribution on the Swiss market of two Sucrosomial® Iron products from the start of 2019, and other two products to be launched by the end of 2020. This is just the latest agreement, following on from the recent partnerships established for the distribution of Sucrosomial® Iron products with Al-Esraa Pharmaceutical Optima for the Egyptian market, and Pharmapoint SA, a Pelion Healthcare Group company, which will be exclusive distributor for Poland of the products in the SiderAL® line.